Drug Profile


Alternative Names: Immune therapeutic vaccine-1; Inactivated pepsin fraction HIV vaccine; IPF-ITV Phases; IPF-ITV-1; Irreversible pepsin fraction HIV vaccine; ITV-1

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator Nonindustrial source
  • Developer Immunotech Laboratories
  • Class AIDS vaccines; Antivirals; Peptide vaccines
  • Mechanism of Action HIV envelope protein gp120 inhibitors; HIV envelope protein gp41 inhibitors; HIV fusion inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis C; HIV infections

Most Recent Events

  • 23 Nov 2016 Pooled safety and efficacy results from the phase I trial released by Immunotech
  • 30 Jul 2016 Immunotech completes a phase I trial in HIV infections in Bulgaria
  • 21 Oct 2014 ITV 1 licensed to Uldic Investment in Sub-Saharan West Africa
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top